The expression of nuclear proteins high mobility group (HMG) I and HMGY was investigated in intraepithelial and invasive lesions of the uterine cervix. Human carcinoma cell lines C-4I, ME-180, and CaSki were used for testing protein expression in neoplastic cells from the cervix. Morphological grading of the dysplasias (CIN 1, CIN 2, and CIN 3) and invasive carcinomas from formalin-fixed paraffin-embedded samples parallels the degree of nuclear immunostaining obtained using a polyclonal antibody raised against the amino-terminal region of HMGI(Y) proteins. The immunostaining obtained with HMGI(Y) antibody was compared with that observed using the antibody Ki-67, and the results were similar. We suggest the use of HMGI(Y) antibody in clinical oncology as a useful marker of intraepithelial lesions and invasive carcinomas.

1

Supported by grants from Associazione Italiana per la Ricerca sul Cancro (Milan, Italy), Consiglio Nazionale delle Ricerche (Rome, Italy), Ministero della Ricerca Scientifica e Tecnologica (Rome, Italy), Università degli Studi di Trieste, and Progetto Finalizzato Applicazioni Cliniche della Ricerca Oncologica. F. M. was a recipient of a fellowship awarded by the Fondazione Italiana per la Ricerca sul Cancro.

This content is only available via PDF.